Pharmacy

The more generic alternatives there are to brand-name drugs, the more likely they will drive down costs for patients and providers. That's the word from a new report from the Journal of the American Medical Association.

Government spending on "compounded" drugs that are handmade by retail pharmacists has skyrocketed, drawing the attention of federal investigators who are raising fraud and overbilling concerns.

A recent study examined this pattern and found the prescriptions are used and renewed more often than you might imagine.

New research published Wednesday found that states that legalized medical marijuana -- which is sometimes recommended for symptoms like chronic pain, anxiety or depression -- saw declines in the number of Medicare prescriptions for drugs used to treat those conditions and a dip in spending by Medicare Part D, which covers the cost on prescription medications.

A new study takes a fresh measure of generic drugs' price advantages, revealing how much more Medicare Part D patients shelled out in copayments for two popular brand-name drugs in 2013. The result: 10.5 times more.

Many clinicians report feeling pressure to overprescribe opioids because scores on the pain management questions are tied to Medicare payments.

After legal battles and lobbying efforts, tens of thousands of people with hepatitis C are gaining earlier access to expensive drugs that can cure this condition.

Anthem and its pharmacy manager Express Scripts overcharged patients with job-based insurance for prescription drugs, alleges a lawsuit that seeks class action status for what could be tens of thousands of Americans.

With more than 350 oncology researchers, data and technology experts, alongside with more 6,000 people at linked events nationwide, it's billed as the the first time a group this big has gathered for such an initiative.

As advocates seek an all-hands-on-deck response to the nation's opioid crisis, many physicians are calling on federal authorities to change these satisfaction surveys.